BIIB News 324.05 08/11/2014 04:53:19 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 324.05 $BIIB

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.41%
Comtex SmarTrend(R) - Thu Aug 07, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.80 to a high of $327.36. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $322.00 on volume of 864,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023
PR Newswire - Thu Aug 07, 12:00PM CDT
Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's Lemtrada, will help drive total sales across the multiple sclerosis (MS) market in the United States, France, Germany, Italy, Spain, United Kingdom and Japan to over $20 billion in 2023, reflecting 4 percent annual growth from 2013. Of note, future generics and projected biosimilar competition will cause major-market sales to contract in the latter part of our study period from a 2018 peak of over $22 billion.

TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta
CNW Group - Thu Aug 07, 9:00AM CDT
Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERATM (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)

Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 07, 8:10AM CDT
Isis Pharmaceuticals (ISIS) remains on track to deliver revenues of more than $160 million this year.

Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
PR Newswire - Wed Aug 06, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended June 30, 2014 and provided a summary of recent corporate highlights.

Five Large Caps With Earnings Growth Of 25% Or More
at The Street - Tue Aug 05, 10:46AM CDT
By James Dennin for Kapitall. A survey of the Fortune 500 by the Wall Street Journal says that United States companies [...]

Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Tue Aug 05, 7:00AM CDT
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement with Biogen Idec (NASDAQ: BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers(TM) division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.

Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.

BioMed Realty Trust To Webcast Investor Day 2014
PR Newswire - Mon Aug 04, 7:00AM CDT
BioMed Realty Trust, Inc. (NYSE: BMR) will webcast its Investor Day 2014 program to be held on Wednesday, August 6, 2014 at the New York Stock Exchange.

Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...

Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs

Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.

Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy

Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:57AM CDT
Biogen Idec could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions

Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.

Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.

Biogen Idec (BIIB) Highlighted As Momo Momentum Stock
at The Street - Wed Jul 30, 9:00AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Hippo's Q3 2024 Results Showcase Growth and Financial Strength

Updated Category News Views 343

Hippo's Remarkable Financial Performance in Q3 2024 Hippo (NYSE: HIPO), a leader in home insurance dedicated to proactive protection, has unveiled its financial highlights for the third quarter of 2024. This announcement celebrates a continuation of their success, driven by strategic initiatives aimed at achieving profitable growth. Strong Revenue Growth Hippo reported...

Continue Reading
Alloy Personal Training's New Partnership Sets Growth Strategy

Updated Category News Views 225

Alloy Personal Training Partners with CapitalSpring for Expansion Alloy Personal Training recently announced an innovative collaboration with a reputable investment firm to boost its franchise growth and reach across the nation. This strategic partnership marks a notable chapter in the company’s history, reinforcing its commitment to a people-centric business model...

Continue Reading
Intel's Strategic Path Forward: Long-Term Growth in Focus

Updated Category News Views 918

Intel's Long-Term Commitment to Foundry Services Intel Corp (NASDAQ: INTC) has recently shared its strategic vision with employees, highlighting a gradual approach to growth instead of seeking quick profits. Analysts report that while there may not be any revolutionary announcements on the horizon, Intel's plans and intentions are coming into clearer focus. Analyst Harlan...

Continue Reading
Game-Changing PR: Good At Marketing's Exclusive Software

Updated Category News Views 41

Earned Media: The Overlooked Goldmine South Florida's advertising scene is a bit like a crowded beach with everyone scrambling for the same spot of sand. But Good At Marketing, based in Boynton Beach, is wading in deeper waters. They've cracked the code to something their competition hasn't even considered: earned media. Not your basic ad buy, this agency says earned...

Continue Reading
Zevra Therapeutics Reveals Impressive 2024 Financial Results

Updated Category News Views 236

Zevra Therapeutics Reports Strong Financial Results for 2024 In a significant step forward, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) has released its financial results for the full year of 2024, reporting impressive net revenues of $23.6 million. This figure includes remarkable fourth-quarter contributions, with net revenue reaching $12.0 million. Company's Strategic Moves...

Continue Reading